TCRT Alaunos Therapeutics, Inc.

NASDAQ
$1.93

Alaunos Therapeutics, Inc. (TCRT) is expected to report earnings on November 13, 2026, before the market open.

Alaunos Therapeutics Reported Earnings
Earnings Date
Nov 13
Friday · Before Open
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alaunos Therapeutics, Inc.

Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes including KRAS, TP53 and EGFR.